DEVELOPMENT OF A MODEL TO ASSESS THE COST-EFFECTIVENESS OF THERAPIES FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FOLLOWING A REFERENCE MODEL FRAMEWORK

被引：0
|
作者：
Aguiar-Ibanez, R. [1 ]
Palencia, R. [2 ]
Kandaswamy, P. [3 ]
Flavin, J. [4 ]
Gauthier, A. [5 ]
Davies, M. J. [6 ]
机构：
[1] Amaris Consulting Uk, London, England
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim Uk, Bracknell, Berks, England
[4] Boehringer Ingelheim Canada Ltd, Burlingon, ON, Canada
[5] Amaris, London, England
[6] Univ Leicester, Leicester, Leics, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1859
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM107
引用
收藏
页码：A562 / A562
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF XIGDUO (EXTENDED-RELEASE DAPAGLIFLOZIN-METFORMIN TABLETS) FOR MANAGING TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS
    Bao, H.
    Liu, Q.
    Peng, X.
    Xuan, J.
    VALUE IN HEALTH, 2024, 27 (06) : S122 - S122
  • [22] COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK BASED ON EMPA-REG OUTCOME DATA
    Daacke, I
    Kandaswamy, P.
    Tebboth, A.
    Kansal, A.
    Reifsnider, O.
    VALUE IN HEALTH, 2016, 19 (07) : A673 - A673
  • [23] Population Pharmacokinetic (POPPK) Model for Ertugliflozin in Healthy Subjects and Type 2 Diabetes Mellitus (T2DM) Patients
    Fediuk, Daryl J.
    Sweeney, Kevin
    Zhou, Susan
    Kumar, Vikas
    Sahasrabudhe, Vaishali
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S25 - S25
  • [24] Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM
    Michael Willis
    Adam Fridhammar
    Jens Gundgaard
    Andreas Nilsson
    Pierre Johansen
    PharmacoEconomics, 2020, 38 : 953 - 969
  • [25] Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM
    Willis, Michael
    Fridhammar, Adam
    Gundgaard, Jens
    Nilsson, Andreas
    Johansen, Pierre
    PHARMACOECONOMICS, 2020, 38 (09) : 953 - 969
  • [26] ADHERENCE AND PERSISTENCE IN PATIENTS INITIATING TREATMENT WITH INJECTABLE THERAPIES FOR TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sicras-Mainar, A.
    Navarro, R.
    Ruiz, L.
    Morano, R.
    VALUE IN HEALTH, 2015, 18 (07) : A612 - A612
  • [27] COST-EFFECTIVENESS ANALYSIS OF DRUG THERAPIES FOR DIABETES MELLITUS TYPE 2 IN CHILE
    Balmaceda, C.
    Abbott, T.
    Armijo, N.
    Zamorano, P.
    Espinoza, M. A.
    VALUE IN HEALTH, 2022, 25 (12) : S127 - S128
  • [28] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS INSULIN-SECRETAGOGUES (SULPHONYLUREAS) OR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS AN ADD-ON TO METFORMIN IN IRELAND
    Bacon, T.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Nuhoho, S.
    Worbes-Cerezo, M.
    VALUE IN HEALTH, 2014, 17 (07) : A346 - A346
  • [29] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
    Pititto, L.
    Neslusan, C.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    Asano, E.
    Puig, A.
    VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
  • [30] Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM)
    Luo, Jian-Quan
    Shu, Yan
    Zhang, Wei
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
12345